AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)

Size: px
Start display at page:

Download "AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)"

Transcription

1 AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa Onpro (peg-filgrastim; G-CSF) Leukine (sargramostim; GM-CSF) Zarxio and Granix (filgrastim; G-CSF) Zarxio is the preferred G-CSF. Requests for non-preferred agents require trial of Zarxio in addition to meeting the clinical criteria detailed below. Authorization guidelines Colony stimulating factors will be covered when the following criteria have been met: Prescribed by, or in consultation with, a hematologist or oncologist Medical records, including labs and weight or BSA, to support diagnosis and dosing is submitted with request Requested agent is dosed and administered within FDA labeled recommendations o Will not be used concomitantly with radiation o Will be administered at the appropriate time after chemotherapy Patient does not have any contraindications to the requested agent o Leukine- patients with excessive leukemic blasts ( 10%) in the bone marrow or peripheral blood) o Neupogen/Zarxio- E-Coli hypersensitivity Will not be used in combination with other myeloid growth factors Additional Criteria Based on Indication: Chemotherapy-Induced Febrile Neutropenia: (Neupogen, Neulasta, Granix, Zarxio, and Leukine) 1. Patient is receiving chemotherapy for a NON-myeloid cancer (i.e., solid tumor, lymphoma) 2. Administered hours after completion of chemotherapy 3. Patient is not receiving radiation therapy 4. Chemotherapy cycle is given no more frequently than every 14 days (For Neulasta only) For PRIMARY prophylaxis: Patient meets ONE of the following: 1. Chemotherapy regimen is given after bone marrow transplant; OR 2. Chemotherapy regimen has >20% risk of febrile neutropenia; OR

2 3. Chemotherapy regimen has 10%-20% risk of febrile neutropenia AND patient has ANY of the following risk factors for febrile neutropenia: a. age > 65 years b. prior chemotherapy or radiation therapy c. persistent neutropenia d. bone marrow involvement by tumor e. Recent surgery and or open wounds f. Liver dysfunction (bilirubin > 2.0) g. Renal dysfunction (CRCL <50) h. HIV For SECONDARY prophylaxis: Patient previously experienced febrile neutropenia from the same chemotherapy regimen and reducing or delaying chemotherapy dose may compromise treatment outcome For TREATMENT of febrile neutropenia in patients who did NOT receive CSF s prophylaxis: Patient has risk factors for poor outcomes resulting from febrile neutropenia (e.g., age > 65, sepsis, severe neutropenia (ANC< 100/mcL), current infection, hospitalized at onset of fever, prior episode of febrile neutropenia) Severe chronic congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia: (Neupogen, Zarxio) 1. Patient has ONE of the following: a. Evidence of inadequate bone marrow reserve (e.g., recurrent fevers, splenomegaly, mucosal ulcers, abdominal pain) b. High risk for developing serious bacterial infection (e.g., primarily severe neutropenia, indwelling venous catheters, prior serious infections) c. Current bacterial infection Neutropenia related to HIV: (Neupogen) 1. Patient has ONE of the following: a. Evidence of inadequate bone marrow reserve (e.g., recurrent fevers, splenomegaly, mucosal ulcers, abdominal pain) b. High risk for developing serious bacterial infection (e.g., primarily severe neutropenia, indwelling venous catheters, prior serious infections) c. Patient has a documented bacterial infection 2. Patient is taking antiretroviral therapy regimen that does NOT contain zidovudine 3. Patient is NOT taking sulfamethaxazole/trimethoprim. NOTE: Patients who require pneumocystis prophylaxis should be switched to atovaquone or dapsone (unless contraindicated) Chemotherapy-induced neutropenia in acute myelogenous leukemia (AML): (Leukine) 1. Patient must be at least 55 years old

3 2. Bone marrow is hypoplastic with < 5% blasts (contraindicated in patients with excessive leukemic blasts ( 10%) in the bone marrow or peripheral blood) 3. Administered on day 11 (or 4 days after the completion) of induction therapy Neupogen and Zarxio may also be reviewed for medical necessity for treatment of the following indications: 1. Acute Myeloid Leukemia in patients receiving induction or consolidation chemotherapy 2. Mobilization of hematopoietic progenitor cells before autologous stem cell transplant 3. Mobilization of hematopoietic progenitor cells in the donor before allogenic stem cell transplant 4. Treatment of acute radiation exposure, to increase survival, in patients who receive myelosuppressive doses of radiation at a dose of 2 gray (Gy) Leukine may also be reviewed for medical necessity for treatment of the following indications: 1. Bone marrow transplant failure or engraftment delay 2. Myeloid reconstitution after allogenic bone marrow transplant 3. Myeloid reconstitution after autologous bone marrow transplant in patients with Hodgkin s disease, non-hodgkin's lymphoma, or acute lymphocytic leukemia 4. Before and after autologous peripheral blood stem cell transplantation Non-FDA Approved Indications (e.g., MDS, HIV, aplastic anemia, drug-induced neutropenia) 1. Medical literature from peer-reviewed journals with safety, efficacy and dosing information for the intended use 2. Recent ANC < 500 if used for treatment of neutropenia Authorization and Limitations Initial Approval: 1. Chemotherapy-induced neutropenia (primary or secondary prophylaxis): Approve per cycle of chemotherapy: up to a 14 day supply for Neupogen, or one 6mg dose of Neulasta (include refills if number of cycles is provided) 2. Treatment of Neutropenia (e.g., congenital, cyclic, or idiopathic, or after chemo + BMT): Approve x 3 3. For non-fda approved indications (e.g., myelodysplastic syndrome, HIV drug-induced neutropenia): a. Short-term therapy: approve per cycle of chemotherapy, or 4 weeks at a time b. Long-term therapy: approve x 6 months Extended Approval: 1. Chemotherapy-induced neutropenia (primary or secondary prophylaxis): a. Recent ANC showing a response to therapy b. Approve per cycle of chemotherapy: up to a 14 day supply for Neupogen, or one 6mg dose of Neulasta c. Include refills if number of cycles is provided

4 2. All other indications: a. Recent ANC b. Recent platelet counts c. Approve up to 1 year, depending on the indication Additional Information: Colony Stimulating Factors are NOT covered for members with the following criteria: Use not approved by the FDA; AND The use is unapproved and not supported by the literature or evidence as an accepted off-label use. Medically Necessary A service or benefit is Medically Necessary if it is compensable under the MA Program and if it meets any one of the following standards: The service or benefit will, or is reasonably expected to, prevent the onset of an illness, condition or disability. The service or benefit will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an illness, condition, injury or disability. The service or benefit will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age. Determination of Medical Necessity for covered care and services, whether made on a Prior Authorization, Concurrent Review, Retrospective Review, or exception basis, must be documented in writing. The determination is based on medical information provided by the Member, the Member s family/caretaker and the Primary Care Practitioner, as well as any other Providers, programs, agencies that have evaluated the Member. All such determinations must be made by qualified and trained Health Care Providers. A Health Care Provider who makes such determinations of Medical Necessity is not considered to be providing a health care service under this Agreement. References: 1. Gold Standard, Inc. Clinical Pharmacology [database online]. Available at: Accessed November 8, Smith TJ, Khatcheressian J, Lyman GH, et al Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. J Clin Oncol

5 24: Available at: Accessed November 8, National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Myeloid Growth Factors V Available at: Accessed October 5, Millman Care Guidelines, 11 th Edition. Available at: Accessed November 8, Russo MW, Zacks SL, Fried MW. Management of newly diagnosed hepatitis C virus infection. Cleveland Clinic J Med; 70(Suppl 4):S Shiffman ML. Side effects of medical therapy for chronic hepatitis C. Ann Hep 2004; 3(1): Jan- March: Granulocyte Stimulating Colony Factor Criteria for Use for Hepatitis C Treatment-Related Neutropenia. VHA Pharmacy Benefits Management Strategic Healthcare Group and Medical Advisory Panel. March 2006 Available at: Accessed October 5, Yee HS, Currie SL, Darling JM, et al. Management and treatment of hepatitis C viral infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol 2006; 101: Aspinall RJ, Pockros PJ. The management of side-effects during therapy for hepatitis C. Aliment Pharmacol Ther 2004;20(9): Yee HS, Currie SL, Darling JM, et al. Management and treatment of hepatitis C viral infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol 2006;101: Leukine (sargramostim) [package insert]. Bridgewater, NJ. April National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infection. V Available at: Accessed October 5, Infectious Disease Society of America: Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. Available at: Accessed October 5, Zarxio (filgrastim-sndz) [package insert]. Princeton, NJ: Sandoz Inc. December Granix (tbo-filgrastim) [package insert]. North Wales, PA: Cephalon, Inc. July 2015.

AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)

AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa

More information

2. Is therapy prescribed by, or in consultation with, a hematologist and/or oncologist?

2. Is therapy prescribed by, or in consultation with, a hematologist and/or oncologist? Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Colony Stimulating Factors (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review

More information

Circle Yes or No Y N. (Note: requests without this information will not be accepted.) [If no, then no further questions.]

Circle Yes or No Y N. (Note: requests without this information will not be accepted.) [If no, then no further questions.] 04/25/2016 Prior Authorization AETA BETTER HEALTH OF LA MEDICAID Colony Stimulating Factors (LA88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,

More information

Pharmacy Prior Authorization

Pharmacy Prior Authorization Pharmacy Prior Authorization MERC CARE (MEDICAID) Colony Stimulating Factors (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign

More information

For peripheral blood stem cell (PBSC) mobilization prior to and during leukapheresis in cancer patients preparing to undergo bone marrow ablation

For peripheral blood stem cell (PBSC) mobilization prior to and during leukapheresis in cancer patients preparing to undergo bone marrow ablation Last Review: 4/2010 NON-FORMULARY Clinical Guideline Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF), Neumega (oprelvekin; rh-il-11), Leukine (sargramostim; GM-CSF) Indications Neupogen

More information

Circle Yes or Y N. [Note: requests without this information will not be accepted.] [If no, then no further questions.

Circle Yes or Y N. [Note: requests without this information will not be accepted.] [If no, then no further questions. 10/01/2016 Prior Authorization Aetna Better Health of West Virginia COLO STIMULATIG FACTORS (WV88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,

More information

Leukine. Leukine (sargramostim) Description

Leukine. Leukine (sargramostim) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Leukine Page: 1 of 6 Last Review Date: November 30, 2018 Leukine Description Leukine (sargramostim)

More information

Leukine. Leukine (sargramostim) Description

Leukine. Leukine (sargramostim) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.08 Subject: Leukine Page: 1 of 5 Last Review Date: September 15, 2017 Leukine Description Leukine

More information

Corporate Medical Policy

Corporate Medical Policy White Blood Cell Growth Factors Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: white_blood_cell_growth_factors 9/2016 4/2017 4/2018 6/2017 Description of

More information

Leukine. Leukine (sargramostim) Description

Leukine. Leukine (sargramostim) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.08 Subject: Leukine Page: 1 of 6 Last Review Date: March 13, 2014 Leukine Description Leukine (sargramostim)

More information

Granix. Granix (tbo-filgrastim) Description

Granix. Granix (tbo-filgrastim) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Subject: Granix 1 of 7 Last Review Date: September 18, 2015 Granix Description Granix (tbo-filgrastim)

More information

Granix. Granix (tbo-filgrastim) Description

Granix. Granix (tbo-filgrastim) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 6 Last Review Date: September 15, 2017 Granix Description Granix (tbo-filgrastim)

More information

Granix. Granix (tbo-filgrastim) Description

Granix. Granix (tbo-filgrastim) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 7 Last Review Date: December 2, 2016 Granix Description Granix (tbo-filgrastim)

More information

Granix. Granix (tbo-filgrastim) Description

Granix. Granix (tbo-filgrastim) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Section: Prescription Drugs Effective Date: April 1, 2014 Subject: Granix 1 of 7 Last Review Date:

More information

Neupogen (Filgrastim)/Neulasta (Pegfilgrastim)

Neupogen (Filgrastim)/Neulasta (Pegfilgrastim) Policy Number Reimbursement Policy NEU12182013RP Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 12/18/2013 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This

More information

Clinical Policy: Sargramostim (Leukine) Reference Number: CP.PHAR.295

Clinical Policy: Sargramostim (Leukine) Reference Number: CP.PHAR.295 Clinical Policy: (Leukine) Reference Number: CP.PHAR.295 Effective Date: 12/16 Last Review Date: 10/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Sargramostim (Leukine) Reference Number: CP.PHAR.295 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important

More information

Colony Stimulating Factors: Zarxio (filgrastim sndz) (Subcutaneous/Intravenous)

Colony Stimulating Factors: Zarxio (filgrastim sndz) (Subcutaneous/Intravenous) Colony Stimulating Factors: Zarxio (filgrastim sndz) (Subcutaneous/Intravenous) Document Number: IC 0245 Last Review Date: 5/1/2018 Date of Origin: 03/31/2015 Dates Reviewed: 03/2015, 05/2015, 08/2015,

More information

LCD for Sargramostim (GM-CSF, Leukine ) (L29275)

LCD for Sargramostim (GM-CSF, Leukine ) (L29275) LCD for Sargramostim (GM-CSF, Leukine ) (L29275) Contractor Information Contractor Name First Coast Service Options, Inc. Contractor Number 09102 Contractor Type MAC - Part B LCD ID Number L29275 LCD Information

More information

Clinical Policy: Pegfilgrastim (Neulasta) Reference Number: CP.CPA.127 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Pegfilgrastim (Neulasta) Reference Number: CP.CPA.127 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: (Neulasta) Reference Number: CP.CPA.127 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for

More information

Pharmacy Prior Authorization Colony Stimulating Factor (CSF)/Myeloid Growth Factor (MGF) Clinical Guideline

Pharmacy Prior Authorization Colony Stimulating Factor (CSF)/Myeloid Growth Factor (MGF) Clinical Guideline Neulasta (peg-filgrastim; G-CSF) Neupogen (filgrastim; G-CSF) Neulasta Onpro (peg-filgrastim; G-CSF) Leukine (sargramostim; GM-CSF) General Authorization Criteria for ALL Agents and Indications: Prescribed

More information

General Authorization Criteria for ALL Agents and Indications:

General Authorization Criteria for ALL Agents and Indications: Neulasta (peg-filgrastim; G-CSF) Neupogen (filgrastim; G-CSF) Neulasta Onpro (peg-filgrastim; G-CSF) Leukine (sargramostim; GM-CSF) General Authorization Criteria for ALL Agents and Indications: Prescribed

More information

AETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA)

AETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA) AETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA) Drugs Covered Procrit Epogen Aranesp Authorization guidelines For patients who meet all of the following: Does

More information

Pharmacy Prior Authorization Colony Stimulating Factors Clinical Guideline. Neulasta Onpro (peg-filgrastim; G-CSF) Leukine (sargramostim; GM-CSF)

Pharmacy Prior Authorization Colony Stimulating Factors Clinical Guideline. Neulasta Onpro (peg-filgrastim; G-CSF) Leukine (sargramostim; GM-CSF) Neulasta (peg-filgrastim; G-CSF) Neupogen (filgrastim; G-CSF) Neulasta Onpro (peg-filgrastim; G-CSF) Leukine (sargramostim; GM-CSF) General Authorization Criteria for ALL Agents and Indications: Prescribed

More information

Colony Stimulating Factors: Nivestym (filgrastim-aafi) (Subcutaneous/Intravenous)

Colony Stimulating Factors: Nivestym (filgrastim-aafi) (Subcutaneous/Intravenous) Colony Stimulating Factors: Nivestym (filgrastim-aafi) (Subcutaneous/Intravenous) Document Number: MODA-0375 Last Review Date: 08/06/2018 Date of Origin: 08/06/2018 Dates Reviewed: 08/2018 I. Length of

More information

WHITE BLOOD CELL COLONY STIMULATING FACTORS

WHITE BLOOD CELL COLONY STIMULATING FACTORS UnitedHealthcare Community Plan Medical Benefit Drug Policy WHITE BLOOD CELL COLONY STIMULATING FACTORS Policy Number: CS2018D0061C Effective Date: June 1, 2018 Table of Contents Page INSTRUCTIONS FOR

More information

WHITE BLOOD CELL COLONY STIMULATING FACTORS

WHITE BLOOD CELL COLONY STIMULATING FACTORS UnitedHealthcare Commercial Medical Benefit Drug Policy WHITE BLOOD CELL COLONY STIMULATING FACTORS Policy Number: PHA043 Effective Date: February 1, 2019 Table of Contents Page INSTRUCTIONS FOR USE...

More information

WHITE BLOOD CELL COLONY STIMULATING FACTORS

WHITE BLOOD CELL COLONY STIMULATING FACTORS ell UnitedHealthcare Oxford Clinical Policy WHITE BLOOD CELL COLONY STIMULATING FACTORS Policy Number: PHARMACY 296.2 T2 Effective Date: April 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS

More information

Hematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte-macrophage colonystimulating factor (G-CSF).

Hematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte-macrophage colonystimulating factor (G-CSF). Hematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte colony-stimulating factor(g-csf). Granulocyte-macrophage colonystimulating factor (G-CSF). Interleukin-11

More information

Tasigna. Tasigna (nilotinib) Description

Tasigna. Tasigna (nilotinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1 of 6 Last Review Date: March 16, 2018 Tasigna Description Tasigna (nilotinib)

More information

UICC EML Review 2014

UICC EML Review 2014 UICC EML Review 2014 Granulocyte Stimulating Agents (G- CSF) Supplemental Document Many antineoplastic agents are cytotoxic to the bone marrow and prevent the development of granulocytes necessary to fight

More information

Tasigna. Tasigna (nilotinib) Description

Tasigna. Tasigna (nilotinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1of 5 Last Review Date: September 15, 2017 Tasigna Description Tasigna (nilotinib)

More information

CLINICAL MEDICATION POLICY

CLINICAL MEDICATION POLICY Policy Name: Policy Number: Approved By: CLINICAL MEDICATION POLICY Adcetris (Brentuximab Vedotin) MP-035-MD-WV Provider Notice Date: 07/03/2017 Original Effective Date: 08/03/2017 Annual Approval Date:

More information

CLINICAL MEDICATION POLICY

CLINICAL MEDICATION POLICY Policy Name: Policy Number: Approved By: CLINICAL MEDICATION POLICY Adcetris (brentuximab vedotin) MP-035-MD-DE Provider Notice Date: 08/01/2017 Original Effective Date: 09/01/2017 Annual Approval Date:

More information

Understanding the role of ex vivo T cell depletion

Understanding the role of ex vivo T cell depletion Prevention of graftversus-host disease (GVHD) Understanding the role of ex vivo T cell depletion Information for patients undergoing allogeneic stem cell transplantation in AML and their families 2 This

More information

Bosulif. Bosulif (bosutinib) Description

Bosulif. Bosulif (bosutinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.22 Section: Prescription Drugs Effective Date: April 1,2018 Subject: Bosulif Page: 1 of 5 Last Review

More information

HMO: Medical (provider setting); Rx (out patient) PPO/CDHP: Rx

HMO: Medical (provider setting); Rx (out patient) PPO/CDHP: Rx BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Epogen, Procrit (epoetin alfa, injection) Commercial HMO/PPO/CDHP

More information

Contents Please refer to Medical Policy I-4, Hemophilia Treatment for additional information.

Contents Please refer to Medical Policy I-4, Hemophilia Treatment for additional information. August 2018 In This Issue Coverage Guidelines Updated for Hemophilia Treatment... 2 Coverage Criteria Revised for Nusinersen (Spinraza)... 6 Coverage Guidelines Developed for Vestronidase Alpha (Mepsevii)...

More information

Class Update with New Drug Evaluation: Colony Stimulating Factors (CSF)

Class Update with New Drug Evaluation: Colony Stimulating Factors (CSF) Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

8/11/2015. Febrile neutropenia Bone marrow transplant Immunosuppressant medications

8/11/2015. Febrile neutropenia Bone marrow transplant Immunosuppressant medications Dean Van Loo Pharm.D. Febrile neutropenia Bone marrow transplant Immunosuppressant medications Steroids Biologics Antineoplastic Most data from cancer chemotherapy Bone marrow suppression Fever is the

More information

Clinical Impact of primary prophylaxis for FN in breast cancer patients. Prof. Young Jin Suh The Catholic University of Korea

Clinical Impact of primary prophylaxis for FN in breast cancer patients. Prof. Young Jin Suh The Catholic University of Korea Clinical Impact of primary prophylaxis for FN in breast cancer patients Prof. Young Jin Suh The Catholic University of Korea Objectives Describe the prevalence of febrile neutropenia in patients with breast

More information

Guidelines in the Management of Febrile Neutropenia for Clinical Practice

Guidelines in the Management of Febrile Neutropenia for Clinical Practice REFERENCES 1. Tangka FK, Trogdon JG, Richardson LC, Howard D, Sabatino SA, Finkelstein EA. Cancer treatment cost in the United States: has the burden shifted over time? Cancer. 2010;116(14):3477-3484.

More information

Reference No: SG 23/13

Reference No: SG 23/13 Title: Author(s) Ownership: Approval by: Guidelines for the use of granulocyte colony stimulating factor (GSCF) in adult oncology & malignant haematology patients Paula Scullin, Consultant Medical Oncologist,

More information

Hematologic Malignancies 2013 Retrospective Study at Truman Medical Center

Hematologic Malignancies 2013 Retrospective Study at Truman Medical Center Hematologic Malignancies 2013 Retrospective Study at Truman Medical Center Kristen Strasser, MD & Abdulraheem Qasem, MD Introduction: Hematologic Malignancies includes malignant diseases of the bone marrow

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY Policy Name: Policy Number: Approved By: CLINICAL MEDICAL POLICY ADCETRIS (Brentuximab Vedotin) MP-035-MD-DE Provider Notice Date: 11/1/2016 Original Effective Date: 12/1/2016 Medical Management Annual

More information

Introduction. Methods. The University of North Carolina Chapel Hill Investigational Review Board approved this study.

Introduction. Methods. The University of North Carolina Chapel Hill Investigational Review Board approved this study. Abstract Background: Salvage chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia (AML) are associated with complete response rates of 30-60%. Determining the superiority

More information

Summary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016

Summary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016 Page 1 of 8 Date: July 22, 2016 Summary of Changes Page BMT CTN 1205 Protocol #4 Dated July 22, 2016 The following changes, and the rationale for the changes, were made to the attached protocol in this

More information

Ready to answer the questions?

Ready to answer the questions? 파워포인트문서의제목 Reference 1. IDSA GUIDELINES. Clinical Practice Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Disease Society of America.

More information

Guideline for the Use of Granulocyte Colony Stimulating Factor (G-CSF) for Adults in Oncology and Haematology

Guideline for the Use of Granulocyte Colony Stimulating Factor (G-CSF) for Adults in Oncology and Haematology (G-CSF) for Adults in Oncology and Haematology For Use in: By: Oncology and Haematology Inpatients and Outpatients Oncologists and Haematologists For: Division responsible for document: Key words: Name

More information

An Overview of Blood and Marrow Transplantation

An Overview of Blood and Marrow Transplantation An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit

More information

Medication Prior Authorization Form

Medication Prior Authorization Form Procrit, Aranesp and (Epoetin Alfa) Policy Number: 1043 Policy History Approve Date: 12/11/2015 Effective Date: 12/11/2015 Preauthorization All Plans Benefit plans vary in coverage and some plans may not

More information

CANCER RELATED INFECTION AND USE OF COLONY STIMULATING FACTORS

CANCER RELATED INFECTION AND USE OF COLONY STIMULATING FACTORS CANCER RELATED INFECTION AND USE OF COLONY STIMULATING FACTORS Suphat Subongkot, Pharm.D, BCPS, BCOP Clinical Pharmacy, Khon Kaen University, Thailand Learning Objectives Summarize national guidelines

More information

What s a Transplant? What s not?

What s a Transplant? What s not? What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence

More information

TIBSOVO (ivosidenib) oral tablet

TIBSOVO (ivosidenib) oral tablet TIBSOVO (ivosidenib) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage

More information

Colony-stimulating factors

Colony-stimulating factors Colony stimulating factors page 1 APC/DTC Briefing Document Colony-stimulating factors Contents Conclusions from clinical evidence 1 Background 2 Clinical guidelines 2 Licensed indications 3 Clinical evidence

More information

Systematic Reviews in Hematological Malignancies

Systematic Reviews in Hematological Malignancies Systematic Reviews in Hematological Malignancies Pia Raanani, MD Davidoff Cancer Center Rabin Medical Center, Israel 1 2 Disorder CHMG Systematic review* Title Protocol Full Review Myelodysplastic syndrome

More information

BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide and DOCEtaxel

BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide and DOCEtaxel BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin Cyclophosphamide DOCEtaxel Protocol Code Tumour Group Contact Physician BRAJFECD Breast Dr. Stephen Chia ELIGIBILITY:

More information

US License Leukine (sargramostim) A Recombinant GM-CSF Yeast-Expressed. Rx only DESCRIPTION

US License Leukine (sargramostim) A Recombinant GM-CSF Yeast-Expressed. Rx only DESCRIPTION US License 1752 Leukine (sargramostim) A Recombinant GM-CSF Yeast-Expressed Rx only DESCRIPTION LEUKINE (sargramostim) is a recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF)

More information

Clinical Policy: Donor Lymphocyte Infusion

Clinical Policy: Donor Lymphocyte Infusion Clinical Policy: Reference Number: PA.CP.MP.101 Effective Date: 01/18 Last Review Date: 11/16 Coding Implications Revision Log This policy describes the medical necessity requirements for a donor lymphocyte

More information

Guidelines for the use of G-CSF in the Department of Oncology

Guidelines for the use of G-CSF in the Department of Oncology Guidelines for the use of G-CSF in the Department of Oncology Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date

More information

VYXEOS (daunorubicin and cytarabine)

VYXEOS (daunorubicin and cytarabine) VYXEOS (daunorubicin and cytarabine) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical

More information

NCCP Chemotherapy Regimen. Brentuximab vedotin Monotherapy

NCCP Chemotherapy Regimen. Brentuximab vedotin Monotherapy Brentuximab INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Status Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): Following autologous stem cell

More information

BC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib

BC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib BC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib Protocol Code Tumour Group Contact Physician ULKAMLAS Leukemia/BMT Dr. Donna Hogge ELIGIBILITY: Acute myeloid

More information

What is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias

What is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements

More information

Shannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008

Shannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008 Shannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008 Study Title: Observational Study to Determine the Effect of an Emergency Department Adult Oncology Stat Antibiotic Protocol on Clinical Outcomes

More information

Neutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt

Neutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt Neutrophil Recovery: The First Step in Posttransplant Recovery No conflicts of interest to disclose Bus11_1.ppt Blood is Made in the Bone Marrow Blood Stem Cell Pre-B White cells B Lymphocyte T Lymphocyte

More information

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow 5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL

More information

NCCP Chemotherapy Regimen. LEAM Autologous Transplant Conditioning Protocol

NCCP Chemotherapy Regimen. LEAM Autologous Transplant Conditioning Protocol INDICATIONS FOR USE: LEAM Autologous Transplant Conditioning Protocol Regimen *Reimbursement INDICATION ICD10 Code Status Autologous conditioning in non-hodgkins Lymphoma (NHL) C85 00468a Hospital Autologous

More information

Stem cell transplantation. Dr Mohammed Karodia NHLS & UP

Stem cell transplantation. Dr Mohammed Karodia NHLS & UP Stem cell transplantation Dr Mohammed Karodia NHLS & UP The use of haemopoeitic stem cells from a donor harvested from peripheral blood or bone marrow, to repopulate recipient bone marrow. Allogeneic From

More information

MANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION

MANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION MANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSP There are no translations available. MANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION

More information

Epogen / Procrit. Epogen / Procrit (epoetin alfa) Description

Epogen / Procrit. Epogen / Procrit (epoetin alfa) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7

More information

Clinical Policy: Rifaximin (Xifaxan) Reference Number: ERX.NPA.40 Effective Date:

Clinical Policy: Rifaximin (Xifaxan) Reference Number: ERX.NPA.40 Effective Date: Clinical Policy: (Xifaxan) Reference Number: ERX.NPA.40 Effective Date: 06.01.15 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

General Terms: Appendix B. National Marrow Donor Program and The Medical College of Wisconsin

General Terms: Appendix B. National Marrow Donor Program and The Medical College of Wisconsin Glossary of Terms This appendix is divided into two sections. The first section, General Terms, defines terms used throughout the CIBMTR data collection forms. The second section, FormsNet TM 2 Terms,

More information

Reference: NHS England 1602

Reference: NHS England 1602 Clinical Commissioning Policy Proposition: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation Reference: NHS England 1602 First published: TBC

More information

Gazyva. Gazyva (obinutuzumab) Description

Gazyva. Gazyva (obinutuzumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.29 Subject: Gazyva Page: 1 of 7 Last Review Date: September 15, 2016 Gazyva Description Gazyva (obinutuzumab)

More information

Gazyva. Gazyva (obinutuzumab) Description

Gazyva. Gazyva (obinutuzumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.29 Subject: Gazyva Page: 1 of 7 Last Review Date: March 16, 2018 Gazyva Description Gazyva (obinutuzumab)

More information

Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand

Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs

More information

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health

More information

Clinical Policy: Valganciclovir (Valcyte) Reference Number: CP.CPA.116 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Valganciclovir (Valcyte) Reference Number: CP.CPA.116 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: (Valcyte) Reference Number: CP.CPA.116 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important

More information

BMTCN REVIEW COURSE PRE-TRANSPLANT CARE

BMTCN REVIEW COURSE PRE-TRANSPLANT CARE BMTCN REVIEW COURSE PRE-TRANSPLANT CARE Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to edit the Master Experts

More information

Kymriah. Kymriah (tisagenlecleucel) Description

Kymriah. Kymriah (tisagenlecleucel) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.101 Subject: Kymriah Page: 1 of 5 Last Review Date: September 20, 2018 Kymriah Description Kymriah

More information

Clinical Policy: Eltrombopag (Promacta) Reference Number: ERX.SPA.71 Effective Date:

Clinical Policy: Eltrombopag (Promacta) Reference Number: ERX.SPA.71 Effective Date: Clinical Policy: (Promacta) Reference Number: ERX.SPA.71 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents

AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents Aetna Better Health 2000 Market Street, Suite 850 Philadelphia, PA 19103 AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents Revised April 2014 Growth

More information

MYELODYSPLASTIC SYNDROMES

MYELODYSPLASTIC SYNDROMES MYELODYSPLASTIC SYNDROMES Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra university hospital, Isfahan university of medical sciences Key Features ESSENTIALS OF DIAGNOSIS Cytopenias

More information

PROMACTA (eltrombopag olamine) oral tablet and oral suspension

PROMACTA (eltrombopag olamine) oral tablet and oral suspension PROMACTA (eltrombopag olamine) oral tablet and oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit

More information

Introduction to Hematopoietic Stem Cell Transplantation

Introduction to Hematopoietic Stem Cell Transplantation Faculty Disclosures Introduction to Hematopoietic Stem Cell Transplantation Nothing to disclose Jeanne McCarthy-Kaiser, PharmD, BCOP Clinical Pharmacist, Autologous Stem Cell Transplant/Long- Term Follow-Up

More information

IVIG (intravenous immunoglobulin) Bivigam, Carimune NF, Flebogamma, Gammagard, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, Privigen

IVIG (intravenous immunoglobulin) Bivigam, Carimune NF, Flebogamma, Gammagard, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, Privigen Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following documented indications: 1. Primary Immunodeficiency Disease (PID) with ONE of the a. Hypogammaglobulinemia,

More information

Transplantation - Challenges for the future. Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust

Transplantation - Challenges for the future. Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust Transplantation - Challenges for the future Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust Bone Marrow Transplantation Timeline, 1957-2006 Appelbaum F. N Engl J Med 2007;357:1472-1475

More information

Canadian supportive care recommendations for the management of neutropenia in patients with cancer

Canadian supportive care recommendations for the management of neutropenia in patients with cancer PRACTICE GUIDELINE SERIES Canadian supportive care recommendations for the management of neutropenia in patients with cancer C.T. Kouroukis MD MSc,* S. Chia MD, S. Verma MD, D. Robson MD, C. Desbiens MD,

More information

12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization

12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization Table of Contents: PART I: Molecular and Cellular Basis of Hematology 1 Anatomy and Pathophysiology of the Gene 2 Genomic Approaches to Hematology 3 Regulation of Gene Expression, Transcription, Splicing,

More information

Nicole Laferriere MD PhD FRCPC April 10, Patient Case Studies: Sticky Situations For Platelet Transfusions

Nicole Laferriere MD PhD FRCPC April 10, Patient Case Studies: Sticky Situations For Platelet Transfusions Nicole Laferriere MD PhD FRCPC April 10, 2019 Patient Case Studies: Sticky Situations For Platelet Transfusions Disclosures Ad Board: Celgene, Jansen, Takeda, Roche, Sanofi, Leo, Shire, Servier, Phizer,

More information

An Introduction to Bone Marrow Transplant

An Introduction to Bone Marrow Transplant Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,

More information

Hematopoietic Stem Cells, Stem Cell Processing, and Transplantation

Hematopoietic Stem Cells, Stem Cell Processing, and Transplantation Hematopoietic Stem Cells, Stem Cell Processing, and Joseph (Yossi) Schwartz, M irector, Hemotherapy and Stem Cell Processing Facility Bone Marrow Can Cure: Leukemia Lymphoma Multiple Myeloma Genetic iseases:

More information

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus

More information

8/15/2017. Hematopoiesis, Growth Factors, and Immunology. Hematopoiesis. Origin of Blood Cells. Objectives

8/15/2017. Hematopoiesis, Growth Factors, and Immunology. Hematopoiesis. Origin of Blood Cells. Objectives Objectives Hematopoiesis, Growth Factors, and Immunology Juanita Madison, MN, RN, AOCN, AOCNS Oncology Clinical Nurse Specialist Swedish Cancer Institute September, 2017 Describe the hematopoietic system

More information

REVISITING THE NEUTROPENIC DIET CASIE MAYNE MS, RD, LD

REVISITING THE NEUTROPENIC DIET CASIE MAYNE MS, RD, LD REVISITING THE NEUTROPENIC DIET CASIE MAYNE MS, RD, LD OBJECTIVES To review the purpose of the Neutropenic diet and non-standardized guidelines. Discuss the current debate to revise nutritional recommendations

More information

GUIDELINES FOR THE USE OF G-CSF & PEGFILGRASTIM (NEULASTA)

GUIDELINES FOR THE USE OF G-CSF & PEGFILGRASTIM (NEULASTA) GUIDELINES FOR THE USE OF G-CSF & PEGFILGRASTIM (NEULASTA) Document Reference: N/A Version: V1.1 Dr Andrew Sykes Document Document June So Owner: Chair Drugs & Author: Director of Pharmacy Therapeutics

More information

Blood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen

Blood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells

More information